The potential association between psychiatric symptoms and the use of levonorgestrel intrauterine devices (LNG-IUDs): A systematic review

References

• Aleknaviciute J, Tulen JHM, De Rijke YB, Bouwkamp CG, van der Kroeg M, Timmermans M, et al. 2017. The levonorgestrel-releasing intrauterine device potentiates stress reactivity. Psychoneuroendocrinology. 80:39–45.
   PubMed Web of Science ®Google Scholar
• Andersson K, Odlind V, Rybo G. 1994. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception. 49(1):56–72.
   PubMed Web of Science ®Google Scholar
• Attia AM, Ibrahim MM, Abou-Setta AM. 2013. Role of the levonorgestrel intrauterine system in effective contraception. Patient Prefer Adherence. 7:777–785.
   PubMed Web of Science ®Google Scholar
• Backman T, Huhtala S, Blom T, Luoto R, Rauramo I, Koskenvuo M. 2000. Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation-wide study of 17,360 users. BJOG. 107(3):335–339.
   PubMedGoogle Scholar
• Backman T, Rauramo I, Jaakkola K, Inki P, Vaahtera K, Launonen A, Koskenvuo M. 2005. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol.;106(4):813–817.
   PubMed Web of Science ®Google Scholar
• Beatty MN, Blumenthal PD. 2009. The levonorgestrel-releasing intrauterine system: safety, efficacy, and patient acceptability. Ther Clin Risk Manag. 5(3):561–574.
   PubMedGoogle Scholar
• Bednarek PH, Jensen JT. 2010. Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS. Int J Womens Health. 1:45–58.
   PubMedGoogle Scholar
• Belvederi Murri M, Ekkekakis P, Magagnoli M, Zampogna D, Cattedra S, Capobianco L, Serafini G, Calcagno P, Zanetidou S, Amore M. 2018. Physical exercise in major depression: reducing the mortality gap while improving clinical outcomes. Front Psychiatry. 9:762.
   PubMed Web of Science ®Google Scholar
• Bitzer J, Rapkin A, Soares CN. 2018. Managing the risks of mood symptoms with LNG-IUS: a clinical perspective. Eur J Contracept Reprod Health Care. 23(5):321–325.
   PubMed Web of Science ®Google Scholar
• Bosco-Levy P, Gouverneur A, Langlade C, Miremont G, Pariente A. 2019. Safety of levonorgestrel 52 mg intrauterine system compared to copper intrauterine device: a population-based cohort study. Contraception. 99(6):345–349.
   PubMed Web of Science ®Google Scholar
• Bottcher B, Radenbach K, Wildt L, Hinney B. 2012. Hormonal contraception and depression: a survey of the present state of knowledge. Arch Gynecol Obstet. 286(1):231–236.
   PubMed Web of Science ®Google Scholar
• Burger Z, Bucher AM, Comasco E, Henes M, Hubner S, Kogler L, Derntl B. 2021. Association of levonorgestrel intrauterine devices with stress reactivity, mental health, quality of life and sexual functioning: a systematic review. Front Neuroendocrinol. 63:100943.
   PubMed Web of Science ®Google Scholar
• Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group TACoO, Gynecologists. 2012. Committee opinion no. 539: adolescents and long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol. 120(4):983–988.
   PubMedGoogle Scholar
• Concin H, Bosch H, Hintermuller P, Hohlweg T, Mursch-Edlmayr G, Pinnisch B, Schmidl-Amann S, Schulz-Greinwald G, Unterlerchner D, Wagner T. 2009. Use of the levonorgestrel-releasing intrauterine system: an Austrian perspective. Curr Opin Obstet Gynecol. 21(Suppl 1):s1–s9.
   PubMedGoogle Scholar
• Conz L, Mota BS, Bahamondes L, Teixeira Doria M, Francoise Mauricette Derchain S, Rieira R, Sarian LO. 2020. Levonorgestrel-releasing intrauterine system and breast cancer risk: a systematic review and meta-analysis. Acta Obstet Gynecol Scand. 99(8):970–982.
   PubMed Web of Science ®Google Scholar
• Cox M, Tripp J, Blacksell S. 2002. Clinical performance of the levonorgestrel intrauterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report. J Fam Plann Reprod Health Care. 28(2):73–77.
   PubMed Web of Science ®Google Scholar
• Datapharm. Mirena 20 micrograms/24 hours intrauterine delivery system; 2022. https://www.medicines.org.uk/emc/product/1132#gref.
   Google Scholar
• Daud S, Ewies AA. Levonorgestrel-releasing intrauterine system: why do some women dislike it? Gynecol Endocrinol. 2008;24(12):686–690.
   PubMed Web of Science ®Google Scholar
• Del Rio JP, Alliende MI, Molina N, Serrano FG, Molina S, Vigil P. 2018. Steroid hormones and their action in women's brains: the importance of hormonal balance. Front Public Health. 6:141.
   PubMed Web of Science ®Google Scholar
• Eisenberg DL, Schreiber CA, Turok DK, Teal SB, Westhoff CL, Creinin MD, ACCESS IUS Investigators. 2015. Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system. Contraception.;92(1):10–16.
   PubMed Web of Science ®Google Scholar
• Elovainio M, Teperi J, Aalto AM, Grenman S, Kivela A, Kujansuu E, Vuorma S, Yliskoski M, Paavonen J, Hurskainen R. 2007. Depressive symptoms as predictors of discontinuation of treatment of menorrhagia by levonorgestrel-releasing intrauterine system. Int J Behav Med. 14(2):70–75.
   PubMed Web of Science ®Google Scholar
• Enzlin P, Weyers S, Janssens D, Poppe W, Eelen C, Pazmany E, Elaut E, Amy J.-J. 2012. Sexual functioning in women using levonorgestrel-releasing intrauterine systems as compared to copper intrauterine devices. J Sex Med. 9(4):1065–1073.
   PubMed Web of Science ®Google Scholar
• Gopimohan R, Chandran A, Jacob J, Bhaskar S, Aravindhakshan R, Aprem AS. 2015. A clinical study assessing the efficacy of a new variant of the levonorgestrel intrauterine system for abnormal uterine bleeding. Int J Gynaecol Obstet. 129(2):114–117.
   PubMed Web of Science ®Google Scholar
• Hall KS, Steinberg JR, Cwiak CA, Allen RH, Marcus SM. 2015. Contraception and mental health: a commentary on the evidence and principles for practice. Am J Obstet Gynecol. 212(6):740–746.
   PubMed Web of Science ®Google Scholar
• Healthline. 2022. Choosing the right IUD: Mirena, Skyla, Liletta, Kyleena, or Paragard? https://www.healthline.com/health/birth-control/mirena-paragard-skyla.
   Google Scholar
• Heikinheimo O, Inki P, Schmelter T, Gemzell-Danielsson K. 2014. Bleeding pattern and user satisfaction in second consecutive levonorgestrel-releasing intrauterine system users: results of a prospective 5-year study. Hum Reprod. 29(6):1182–1188.
   PubMed Web of Science ®Google Scholar
• Horibe M, Hane Y, Abe J, Matsui T, Kato Y, Ueda N, Sasaoka S, Motooka Y, Hatahira H, Hasegawa S. 2018. Contraceptives as possible risk factors for postpartum depression: a retrospective study of the food and drug administration adverse event reporting system, 2004–2015. Nurs Open. 5(2):131–138.
   PubMed Web of Science ®Google Scholar
• Hurskainen R, Teperi J, Rissanen P, Aalto AM, Grenman S, Kivela A, Kujansuu E, Vuorma S, Yliskoski M, Paavonen J. 2004. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA. 291(12):1456–1463.
   PubMed Web of Science ®Google Scholar
• Kaiser Family Foundation. 2020. Intrauterine devices (IUDs): access for women in the U.S. https://www.kff.org/womens-health-policy/fact-sheet/intrauterine-devices-iuds-access-for-women-in-the-u-s/.
   Google Scholar
• Kaneshiro B, Aeby T. 2010. Long-term safety, efficacy, and patient acceptability of the intrauterine copper T-380A contraceptive device. Int J Womens Health. 2:211–220.
   PubMedGoogle Scholar
• Keyes KM, Cheslack-Postava K, Westhoff C, Heim CM, Haloossim M, Walsh K, Koenen K. 2013. Association of hormonal contraceptive use with reduced levels of depressive symptoms: a national study of sexually active women in the United States. Am J Epidemiol. 178(9):1378–1388.
   PubMed Web of Science ®Google Scholar
• Langlade C, Gouverneur A, Bosco-Levy P, Gouraud A, Perault-Pochat MC, Bene J, Iremont-Salamé G, Pariente A, French Network of Pharmacovigilance Centres. 2019. Adverse events reported for Mirena levonorgestrel-releasing intrauterine device in France and impact of media coverage. Br J Clin Pharmacol. 85(9):2126–2133.
   PubMed Web of Science ®Google Scholar
• Lu M, Yang X. 2018. Levonorgestrel-releasing intrauterine system for treatment of heavy menstrual bleeding in adolescents with Glanzmann's thrombasthenia: illustrated case series. BMC Womens Health. 18(1):45.
   PubMedGoogle Scholar
• Mansour D. 2012. The benefits and risks of using a levonorgestrel-releasing intrauterine system for contraception. Contraception. 85(3):224–234.
   PubMed Web of Science ®Google Scholar
• McCloskey LR, Wisner KL, Cattan MK, Betcher HK, Stika CS, Kiley JW. 2021. Contraception for women with psychiatric disorders. Am J Psychiatry. 178(3):247–255.
   PubMed Web of Science ®Google Scholar
• Medscape. 2022. Drugs & diseases – levonorgestrel intrauterine (Rx). https://reference.medscape.com/drug/mirena-skyla-levonorgestrel-intrauterine-342780.
   Google Scholar
• Nelson AL. 2017. Levonorgestrel-releasing intrauterine system (LNG-IUS 12) for prevention of pregnancy for up to five years. Expert Rev Clin Pharmacol. 10(8):833–842.
   PubMed Web of Science ®Google Scholar
• Nilsson CG, Luukkainen T, Diaz J, Allonen H. 1982. Clinical performance of a new levonorgestrel-releasing intrauterine device. A randomized comparison with a nova-T-copper device. Contraception. 25(4):345–56.
   PubMed Web of Science ®Google Scholar
• Nutt DJ. 2008. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry. 69(Suppl E1):4–7.
   PubMed Web of Science ®Google Scholar
• Pagano HP, Zapata LB, Berry-Bibee EN, Nanda K, Curtis KM. 2016. Safety of hormonal contraception and intrauterine devices among women with depressive and bipolar disorders: a systematic review. Contraception. 94(6):641–649.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. 2021. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 372:n71.
   PubMed Web of Science ®Google Scholar
• Peck R, Rella W, Tudela J, Aznar J, Mozzanega B. 2016. Does levonorgestrel emergency contraceptive have a post-fertilization effect? A review of its mechanism of action. Linacre Q. 83(1):35–51.
   PubMed Web of Science ®Google Scholar
• Reinecke I, Hofmann B, Mesic E, Drenth HJ, Garmann D. 2018. An integrated population pharmacokinetic analysis to characterize levonorgestrel pharmacokinetics after different administration routes. J Clin Pharmacol. 58(12):1639–1654.
   PubMed Web of Science ®Google Scholar
• Roberts TA, Hansen S. 2017. Association of hormonal contraception with depression in the postpartum period. Contraception. 96(6):446–452.
   PubMed Web of Science ®Google Scholar
• Robinson R, China S, Bunkheila A, Powell M. 2008. Mirena intrauterine system in the treatment of menstrual disorders: a survey of UK patients' experience, acceptability and satisfaction. J Obstet Gynaecol. 28(7):728–731.
   PubMedGoogle Scholar
• Salmi A, Pakarinen P, Peltola AM, Rutanen EM. 1998. The effect of intrauterine levonorgestrel use on the expression of c-JUN, oestrogen receptors, progesterone receptors and Ki-67 in human endometrium. Mol Hum Reprod. 4(12):1110–1115.
   PubMed Web of Science ®Google Scholar
• Santoro N, Teal S, Gavito C, Cano S, Chosich J, Sheeder J. 2015. Use of a levonorgestrel-containing intrauterine system with supplemental estrogen improves symptoms in perimenopausal women: a pilot study. Menopause. 22(12):1301–1307.
   PubMed Web of Science ®Google Scholar
• Schaffir J, Worly BL, Gur TL. 2016. Combined hormonal contraception and its effects on mood: a critical review. Eur J Contracept Reprod Health Care. 21(5):347–355.
   PubMed Web of Science ®Google Scholar
• Serafini G, Pompili M, Innamorati M, Gentile G, Borro M, Lamis DA, Lala N, Negro A, Simmaco M, Girardi P, et al. 2012. Gene variants with suicidal risk in a sample of subjects with chronic migraine and affective temperamental dysregulation. Eur Rev Med Pharmacol Sci. 16(10):1389–1398.
   PubMed Web of Science ®Google Scholar
• Sivin I, Stern J, International Committee for Contraception Research (ICCR). 1994. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. Fertil Steril. 61(1):70–77.
   PubMed Web of Science ®Google Scholar
• Skovlund CW, Morch LS, Kessing LV, Lange T, Lidegaard O. 2018. Association of hormonal contraception with suicide attempts and suicides. Am J Psychiatry. 175(4):336–342.
   PubMed Web of Science ®Google Scholar
• Skovlund CW, Morch LS, Kessing LV, Lidegaard O. 2016. Association of hormonal contraception with depression. JAMA Psychiatry. 73(11):1154–1162.
   PubMed Web of Science ®Google Scholar
• Slattery J, Morales D, Pinheiro L, Kurz X. 2018. Cohort study of psychiatric adverse events following exposure to levonorgestrel-containing intrauterine devices in UK general practice. Drug Saf. 41(10):951–958.
   PubMed Web of Science ®Google Scholar
• Smiech A, Rabe-Jabłońska J. 2006. Psychiatric disorders connected with hormonal contraception. Psychiatria i Psychologia Kliniczna. 6:110–117 + 32.
   Google Scholar
• Soares CN, Zitek B. 2008. Reproductive hormone sensitivity and risk for depression across the female life cycle: a continuum of vulnerability? J Psychiatry Neurosci. 33(4):331–343.
   PubMed Web of Science ®Google Scholar
• Sturridge F, Guillebaud J. 1996. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system. Drug Saf. 15(6):430–440.
   PubMed Web of Science ®Google Scholar
• Tazegul Pekin A, Secilmis Kerimoglu O, Kebapcilar AG, Yilmaz SA, Benzer N, Celik C. 2014. Depressive symptomatology and quality of life assessment among women using the levonorgestrel-releasing intrauterine system: an observational study. Arch Gynecol Obstet. 290(3):507–511.
   PubMed Web of Science ®Google Scholar
• Ti A, Curtis KM. 2019. Postpartum hormonal contraception use and incidence of postpartum depression: a systematic review. Eur J Contracept Reprod Health Care. 24(2):109–116.
   PubMed Web of Science ®Google Scholar
• Toffol E, Heikinheimo O, Koponen P, Luoto R, Partonen T. 2012. Further evidence for lack of negative associations between hormonal contraception and mental health. Contraception. 86(5):470–480.
   PubMed Web of Science ®Google Scholar
• Toffol E, Heikinheimo O, Koponen P, Luoto R, Partonen T. 2011. Hormonal contraception and mental health: results of a population-based study. Hum Reprod. 26(11):3085–3093.
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2020. Family planning/contraception methods. https://www.who.int/news-room/fact-sheets/detail/family-planning-contraception.
   Google Scholar
• Worly BL, Gur TL, Schaffir J. 2018. The relationship between progestin hormonal contraception and depression: a systematic review. Contraception. 97(6):478–489.
   PubMed Web of Science ®Google Scholar
• Zeiss R, Schonfeldt-Lecuona C, Gahr M, Graf H. 2020. Depressive disorder with panic attacks after replacement of an intrauterine device containing levonorgestrel: a case report. Front Psychiatry. 11:561685.
   PubMed Web of Science ®Google Scholar